VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 3, 2026

Stock Comparison

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. vs Novartis AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

600809 · Shanghai Stock Exchange

Market cap (USD)$209.5B
Gross margin (TTM)76.1%
Operating margin (TTM)44.3%
Net margin (TTM)32.7%
SectorConsumer
IndustryBeverages - Wineries & Distilleries
CountryCN
Data as of2025-12-30
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Shanxi Xinghuacun Fen Wine Factory Co., Ltd.'s moat claims, evidence, and risks.

View 600809 analysis

Novartis AG

NOVN · SIX Swiss Exchange

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryCH
Data as of2026-01-02
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novartis AG's moat claims, evidence, and risks.

View NOVN analysis

Comparison highlights

  • Moat score gap: Novartis AG leads (65 / 100 vs 57 / 100 for Shanxi Xinghuacun Fen Wine Factory Co., Ltd.).
  • Segment focus: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 2 segments (73.7% in Mid-to-High Priced Liquor (>= RMB130/L)); Novartis AG has 5 segments (29.3% in Oncology).
  • Moat breadth: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 5 moat types across 2 domains; Novartis AG has 4 across 3.

Primary market context

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

Mid-to-High Priced Liquor (>= RMB130/L)

Market

China premium baijiu (with focus on light-aroma baijiu) and mid-to-high priced spirits

Geography

China

Customer

Consumers and corporate/banquet demand via distributor/retail channels

Role

Brand owner / distiller / wholesaler-distributor orchestrator

Revenue share

73.7%

Novartis AG

Oncology

Market

Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)

Geography

Global

Customer

Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels

Role

Originator developer, manufacturer, and marketer of oncology therapies

Revenue share

29.3%

Side-by-side metrics

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.
Novartis AG
Ticker / Exchange
600809 - Shanghai Stock Exchange
NOVN - SIX Swiss Exchange
Market cap (USD)
$209.5B
n/a
Gross margin (TTM)
76.1%
n/a
Operating margin (TTM)
44.3%
n/a
Net margin (TTM)
32.7%
n/a
Sector
Consumer
Healthcare
Industry
Beverages - Wineries & Distilleries
n/a
HQ country
CN
CH
Primary segment
Mid-to-High Priced Liquor (>= RMB130/L)
Oncology
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
57 / 100
65 / 100
Moat domains
Demand, Supply
Legal, Supply, Demand
Last update
2025-12-30
2026-01-02

Moat coverage

Shared moat types

Brand Trust

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. strengths

Learning Curve YieldDistribution ControlPreferential Input AccessScale Economies Unit Cost

Novartis AG strengths

IP Choke PointRegulated Standards PipeCapex Knowhow Scale

Segment mix

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. segments

Full profile >

Mid-to-High Priced Liquor (>= RMB130/L)

Oligopoly

73.7%

Other Liquor (value-tier baijiu and other spirits)

Competitive

25.9%

Novartis AG segments

Full profile >

Cardiovascular, Renal and Metabolic

Oligopoly

17%

Immunology

Oligopoly

18.5%

Neuroscience

Oligopoly

9.4%

Oncology

Oligopoly

29.3%

Established Brands

Competitive

25.8%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.